Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.

MLA

Voskamp, Astrid L., et al. “Phase 1 Trial Supports Safety and Mechanism of Action of Peptide Immunotherapy for Peanut Allergy.” Allergy, vol. 79, no. 2, Feb. 2024, pp. 485–98. EBSCOhost, https://doi.org/10.1111/all.15966.

APA

Voskamp, A. L., Khosa, S., Phan, T., DeBerg, H. A., Bingham, J., Hew, M., Smith, W., Abramovitch, J., Rolland, J. M., Moyle, M., Nadeau, K. C., Lack, G., Larché, M., Wambre, E., O’Hehir, R. E., Hickey, P., & Prickett, S. R. (2024). Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy. Allergy, 79(2), 485–498. https://doi.org/10.1111/all.15966

Chicago

Voskamp, Astrid L, Sugandhika Khosa, Tracy Phan, Hannah A DeBerg, Judy Bingham, Mark Hew, William Smith, et al. 2024. “Phase 1 Trial Supports Safety and Mechanism of Action of Peptide Immunotherapy for Peanut Allergy.” Allergy 79 (2): 485–98. doi:10.1111/all.15966.